Update and Review,citrullinated peptides are

Citrullinated peptides are a key focus in understanding the intricate mechanisms behind rheumatoid arthritis (RA). These modified protein fragments arise from a process called citrullination, which involves the enzymatic deimination of arginine residues within proteins. While protein citrullination can occur in various physiological contexts, its aberrant presence and the subsequent immune response are strongly implicated in the pathogenesis of RA.

The primary source of citrullinated peptides in the context of rheumatoid arthritis originates from the action of peptidylarginine deiminases (PADs). These enzymes, particularly PAD2 and PAD4, are found in various cells, including macrophages and neutrophils, which are abundant at sites of inflammation. During inflammatory processes, which are a hallmark of RA, these PAD enzymes become activated. They can then convert the amino acid arginine into citrulline in specific proteins. This modification can alter the protein's structure and function, making it a target for the immune system.

Several mechanisms of cell death have been implicated in generating these citrullinated autoantigens in RA, including autophagy, NETosis, and necrosis. These processes can release intracellular proteins that are then subjected to citrullination by PAD enzymes. Consequently, these modified proteins, or citrullinated protein, can trigger an autoimmune response.

Fibrinogen-derived citrullinated peptides have been particularly well-studied due to their high capacity to be recognized by anticitrullinated protein antibodies (ACPAs) found in patients with RA. Other proteins that can undergo citrullination and contribute to the citrullinome (the totality of citrullinated proteins) include vimentin, collagen, and alpha-enolase.

The presence of citrullinated peptides is not confined to the joints. While citrullinated peptides are found in high concentrations in the synovial fluid of rheumatoid arthritis patients, with one study identifying 182 citrullinated peptides and 200 citrullinated sites in RA synovial fluid, they can also be generated at extra-articular sites prior to the onset of overt disease. This suggests that the autoimmune process targeting citrullinated protein may begin before clinical symptoms of rheumatoid arthritis manifest.

The immune system's response to these citrullinated peptides is critical. The body produces Anticitrullinated Peptide Antibodies (ACPA), which are highly specific serologic markers for RA. These anticitrullinated protein antibodies, including the widely used Anti-CCP (anti-cyclic citrullinated peptide) tests, can pre-date clinical symptoms by years. The generation of ACPAs within the synovium, and potentially at other inflammatory sites, leads to the formation of immune complexes. These complexes can then contribute to the chronic inflammation and joint damage characteristic of rheumatoid arthritis.

Furthermore, the RA-associated HLA-DR molecules play a role in how these citrullinated peptides are presented to the immune system. While some studies suggest that RA-associated HLA-DR molecules do not bind citrullinated peptides as well as their non-citrullinated counterparts, others indicate a specific binding preference that facilitates the autoimmune response. Understanding this interaction is crucial for developing targeted therapies.

In summary, citrullinated peptides in rheumatoid arthritis originate from the enzymatic modification of arginine residues in proteins by PAD enzymes, often occurring during inflammatory cell death. These modified peptides, particularly fibrinogen-derived citrullinated peptides, are then recognized by the immune system, leading to the production of ACPAs, which are central to the diagnosis and pathogenesis of RA. The presence of citrullinated protein can be detected in various locations, including the synovium, and their identification has significantly advanced our understanding of rheumatoid arthritis pathogenesis.